Holen Sie sich die Stockscreener-App
3.05
5.28%
-0.17
Handel nachbörslich:
3.02
-0.03
-0.98%
Schlusskurs vom Vortag:
$3.22
Offen:
$3.15
24-Stunden-Volumen:
4.51M
Relative Volume:
0.38
Marktkapitalisierung:
$449.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-5.3509
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
-9.50%
1M Leistung:
+362.05%
6M Leistung:
+82.63%
1J Leistung:
+42.52%
1-Tages-Spanne:
$2.87
$3.25
1-Wochen-Bereich:
$2.87
$4.05
52-Wochen-Spanne:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Vergleichen Sie PROK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
3.05 | 449.62M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - Yahoo Finance
Is ProKidney Corp. a good long term investmentExtraordinary market timing - jammulinksnews.com
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
ProKidney Corp. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) - Insider Monkey
ProKidney Corp. (PROK): Navigating Clinical Pivotality and Market Volatility in the Race for a CKD Breakthrough - AInvest
JP Morgan Maintains Neutral Stance on ProKidney Corp., Citing Extended Timeline for Key Data - AInvest
What analysts say about ProKidney Corp. stockAccelerated wealth expansion - Autocar Professional
What drives ProKidney Corp. stock priceFree Capital Allocation Plans - jammulinksnews.com
New Strong Buy Stocks for July 17th - MSN
10 Hot Penny Stocks to Invest in Now - Insider Monkey
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - Mitrade
Best Momentum Stocks to Buy for July 17th - TradingView
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal
ProKidney completes Delaware domestication and restructures corporate agreements By Investing.com - Investing.com Nigeria
ProKidney completes Delaware domestication and restructures corporate agreements - Investing.com
Citi Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Will ProKidney’s Recent Surge Last? - StocksToTrade
ProKidney’s Clinical Trials and Regulatory Developments Lead to Hold Rating Amid Uncertainty - TipRanks
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline - TipRanks
ProKidney’s Strategic FDA Alignment and Promising Clinical Data Drive Buy Rating - TipRanks
ProKidney price target raised to $7 from $6 at Guggenheim - MSN
ProKidney’s Dramatic Shares Tumble - timothysykes.com
Is ProKidney’s Slide a Buy Signal? - StocksToTrade
ProKidney Shares Plummet Amid Downgrades - timothysykes.com
UBS Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
ProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug Trial - MarketScreener
ProKidney Stock Skyrockets: What Does This Mean? - StocksToTrade
ProKidney, FDA align on accelerated approval pathway for Rilparencel - MSN
UBS Adjusts ProKidney Price Target to $8 From $4, Maintains Buy Rating - MarketScreener
ProKidney stock soars after FDA confirms accelerated approval pathway - Investing.com
Sector Update: Health Care - MarketScreener
ProKidney Soars 29.27% on FDA Milestone for CKD Therapy - AInvest
ProKidney Says FDA Confirms Accelerated Approval Pathway for Rilparencel - MarketScreener
Prokidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - MarketScreener
ProKidney stock falls after FDA alignment on rilparencel approval pathway - Investing.com
ProKidney announces alignment with the FDA on the accelerated approval pathway for rilparencel - grafa.com
ProKidney Secures FDA Alignment for Rilparencel Approval - TipRanks
Why Did ProKidney Stock Plunge 5.15% Despite 169% YTD Surge? - AInvest
ProKidney stock falls after FDA alignment on rilparencel approval pathway By Investing.com - Investing.com Nigeria
ProKidney stock price target raised to $8 from $4 at UBS on promising data By Investing.com - Investing.com South Africa
ProKidney stock price target raised to $8 from $4 at UBS on promising data - Investing.com India
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):